The Effect of Ginkgo Biloba Leaf Dropping Pill Combined with Butylphthalide Capsule on Cognitive Dysfunction in Patients after Acute Ischemic Stroke and Its Impact on Serum Cytokines

Objective: To investigate the therapeutic effect of Ginkgo biloba extract dropping pills combined with butylphthalide capsules on cognitive dysfunction in patients after acute ischemic stroke (AIS) and its impact on serum cytokines CRP, IL-6, and Hcy. Methods: This study selected 76 patients with cognitive dysfunction after ischemic stroke who were hospitalized at Zhuji People’s Hospital from January 2023 to January 2024. The patients were divided into two groups. The control group was treated with butylphthalide capsules, while the combination group received Ginkgo biloba extract dropping pills in addition to the treatment given to the control group. The neurological function, cognitive function, activities of daily living, and levels of serum cytokines CRP, IL-6, and Hcy were compared between the two groups after 1 month and 3 months of treatment. Results: The NIHSS scores, MMSE scores, ADL scores, and levels of CRP, IL-6, and Hcy in both groups showed statistically significant differences compared to before treatment (P Conclusion: The combination of Ginkgo biloba extract dropping pills and butylphthalide capsules has a better therapeutic effect on cognitive dysfunction in patients after ischemic stroke. It can improve the neurological function and cognitive function of patients, enhance their ability to perform daily activities, and reduce inflammatory responses.

Neuroprotective effects of Ginkgo biloba dropping pills in Parkinson's disease

Parkinson's disease(PD) is the second most common neurodegenerative disease in the world;however,it lacks effective and safe treatments. Ginkgo biloba dropping pill(GBDP), a unique Chinese G. biloba leaf extract preparation, exhibits antioxidant and neuroprotective effects and has a potential as an alternative therapy for PD. Thus, the aims of this study were to evaluate the effects of GBDP in in vitro and in vivo PD models and to compare the chemical constituents and pharmacological activities of GBDP and the G. biloba extract EGb 761. Using liquid chromatography tandem-mass spectrometry, 46 GBDP constituents were identified. Principal component analysis identified differences in the chemical profiles of GBDP and EGb 761. A quantitative analysis of 12 constituents showed that GBDP had higher levels of several flavonoids and terpene trilactones than EGb 761, whereas EGb 761 had higher levels of organic acids.Moreover, we found that GBDP prevented 6-hydroxydopamine-induced dopaminergic neuron loss in zebrafish and improved cognitive impairment and neuronal damage in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced PD mice. Although similar effects were observed after EGb 761 treatment,the neuroprotective effects were greater after GBDP treatment on several endpoints. In addition, in vitro results suggested that the Akt/GSK3β pathway may be involved in the neuroprotective effects of GBDP.These findings demonstrated that GBDP have potential neuroprotective effects in the treatment of PD.

Shexiang Tongxin Dropping Pill combined with thrombus aspiration improves myocardial perfusion after PCI in patients with STEMI: the clinical research

Objective:To study the effect of Shexiang Tongxin Dropping Pill combined with thrombus aspiration on improving myocardial perfusion after PCI in patients with STEMI.Methods:A total of 104 patients with STEMI who received emergency PCI combined with thrombus aspiration in our hospital between May 2013 and October 2015 were selected as the research subjects and randomly divided into two groups: observation group received perioperative antiplatelet combined with Shexiang Tongxin Dropping Pill therapy, and the control group received perioperative antiplatelet therapy alone. Before treatment and 3 days after treatment, serum myocardial injury indexes, endothelial injury indexes and RAS system indexes were determined;4 weeks after treatment, serum ventricular remodeling indexes were determined. Results:3 d after treatment, serum CK, CK-MB, cTnI, cTnT, ET-1, vWF, PRA, AngII and ALD levels of both groups were significantly lower than those before treatment while NO level was significantly higher than that before treatment;serum CK, CK-MB, cTnI, cTnT, ET-1, vWF, PRA, AngII and ALD levels of observation group 3 d after treatment were significantly lower than those of control group while NO level was significantly higher than that of control group;4 weeks after treatment, serum PICP, ICTP, PIIINP, HSP47 and GDF-15 levels of observation group were significantly lower than those of control group.Conclusion: Shexiang Tongxin Dropping Pill application during perioperative period of PCI combined with thrombus aspiration can reduce myocardial cell damage and endothelial function injury as well as inhibit RAS system activation and ventricular remodeling.

Protective effect of gingerol dropping pills against alcoholic liver injury in mice

OBJECTIVE To prepare gingerol dropping pills and to investigate its protective effect on alcoholic liver injury. METHODS The prescription was selected by orthogonal design method and the effect of the option and ratio of ground substance,the temperature of drug. The hardness,circular degree,the tail formation and the dissolution time were studied. Totally 40 KM mice were randomly divided into control group,model group,gingerol dropping pill group(400 mg·kg^(-1)·d^(-1)) and positive control group(bifendate,150 mg·kg^(-1)·d^(-1)) of 10 mice each. The mice from the model and two drug groups were administrated with liqueur[0.15 mL/(10 g·d)]daily by gavage for 3 weeks,Two hours later,drug group mice were treated corresponding gingerol dropping pill and bifendate. Meanwhile,the control group were gavaged same amount of normal saline. Finally,when the model of acute alcoholic liver injury was established on the 22 stday,Biochemical indicators of ocular blood in mice were observed.We also observed the change of liver morphology. RESULTS Under optimum conditions,we can obtain dropping pills having circular shape,touching with hardness and short dissolution time. Compared with the control group,the levels of alanine transaminase(ALT),glutamic-oxaloacetic transaminase(AST) and malondialdehyde(MDA) in model group were obviously increased(P<0.01),While the activity of Superoxide dismutase(SOD) were decreased. In addition,In model group,mice liver disorders,hepatic lobule fusion,accompanying a large number of patchy sample liver cell vacuoles,various sizes of fat vacuoles appeared in cytoplasm and inflammatory cell infiltration were visible around the central vein. On the contrary,compared with the model group,drug groups attenuated or even reversed hepatic pathological changes. Form gingerol dropping pill group,an increase in hepatic SOD activity and serum ALT and AST activities were found and a significant decrease in hepatic MDA content were also observed(P<0.01). CONCLUSION The prescription of gingerol dropping pills was reasonable,and the preparation process was simple. Gingerol dropping pills can protect liver from alcoholic liver injury to some extend,and the mechanism may be related to its antioxidant effect.

A theoretical study of miRNA155-DNA methylation mediated mitokATP regulating mitochondrial autophagy in the improvement of myocardial ischemia-reperfusion injury by Qishen Yiqi Dropping Pills

In the state of acute myocardial ischemia,miRNA expression can regulate related genes and proteins,reduce myocardial cell damage,and thus play a protective role in the myocardium.However,the specific mechanism still needs to be further explored.Recent studies have found that the opening of the mitoKATP channel can regulate mitochondrial autophagy,and the initiation of miRNA-DNA methylation plays a regulatory role in inducing cell autophagy.The applicant research team previously found that Qishen Yiqi Dropping Pills could significantly improve myocardial ischemia by mediating MitokATP channels to regulate mitochondrial autophagy.,and animal experiments have confirmed that miR-155 plays a significant role in the aspect of autophagy regulates,inflammatory reaction and Vascular smooth muscle cell migration.Therefore,the applicant innovatively proposed that Qishen Yiqi Dropping Pills can regulate miRNA155-DNA methylation to mediate the opening of mitoKATP,thereby regulating mitochondrial autophagy and improving myocardial ischemia.In this paper,the association between mitochondrial autophagy and oxidative stress injury after myocardial ischemia was described,and the possible mechanism of Qisen Yiqi dropping pills regulating mitochondrial autophagy by regulating miRNA155-DNA methylation to mediate MitokATP to improve myocardial ischemia reperfusion injury was discussed,so as to provide theoretical ideas for related research.

Meta-analysis of the clinical efficacy of Liqi Huoxue drop pill in the treatment of angina pectoris in coronary artery disease

Objective:To evaluate the efficacy of Liqi Huoxue dropping pills in the treatment of angina pectoris in coronary heart disease using the Meta-analysis system.Methods:Randomized controlled trials(RCT)on the treatment of angina pectoris in coronary artery disease with the combination of Western medicine with Liqi Huoxue drop pills were searched using computerized search databases,including English databases PubMed,Embase,Web of Science,The Cochrane Library and Chinese databases CNKI,VIP,WanFang Data and CBM from the time of establishment until February 1,2022.Data extraction was performed independently by two investigators and the quality of the literature of the included studies was assessed.A meta-analysis of the included literature was performed using Revman 5.4 software.Results:Nine studies with a total of 982 patients were included.The results of Meta-analysis showed that the observation group,which adopted conventional treatment of Western medicine combined with Li qi huo xue dropping pills,was better than the control group,which was treated with conventional Western medicine alone.Clinical efficacy of the intervention group[R R=1.20,95%CI=(1.12,1.29),P<0.00001],Angina pectoris symptom treatment[RR=1.17,95%CI=(1.07,1.29),P=0.0010],Number of angina attacks[SMD=-2.26,95%CI(-4.10,-0.42),P=0.002],IL-6[MD=-4.65,95%CI(-6.91,-2.39),P<0.0001],IL-18[MD=-2.53,95%CI(-2.84,-2.22),P<0.00001],HS-CRP[MD=-0.08,95%CI(-1.81,-0.75),P<0.00001],and NO[M D=8.03,95%CI(0.93,15.14),P=0.03]were significantly different and better than the control group(western conventional treatment),and the differences were all statistically significant.Conclusion:Combining Liqi Huoxue drop pill with conventional Western medicine for patients with coronary angina can effectively improve the clinical efficacy,the efficacy of angina symptoms,the number of angina attacks,serum inflammatory indexes interleukin-6,interleukin-18,high-sensitivity C-reactive protein,and endothelial function NO indexes in patients with coronary angina,providing a reliable evidence-based basis for combining Liqi Huoxue drop pill with Western medicine for the treatment of coronary angina.

Hippocampal CA1 pyramidal cells and neurotrophic factors in a rat model of vascular dementia following Xiongma drop pill versus Ginkgo leaf tablets

BACKGROUND： Previous studies have demonstrated the neuroprotective effects of Xiongma drop pill （XMDP） in a mouse model of vascular dementia. Neurotrophic factors play an important role in repair and regeneration of injured neurons. OBJECTIVE： To compare the effects of XMDP and Ginkgo leaf tablets on the appearance and number of hippocampal CA1 pyramidal neurons, as well as neurotrophic factor content in brain tissues, during vascular dementia formation to explore the neuroprotective mechanisms of XMDP. DESIGN, TIME AND SETTING： A randomized, controlled, animal experiment was performed at the Laboratory of Pharmacology, College of Pharmacy, Harbin University of Commerce between April 2007 and December 2008. MATERIALS： XMDP was prepared by the College of Pharmacy, Harbin University of Commerce, with each 40 mg pill containing ferulic acid （≥ 0.149 mg） and gastrodin （≥ 0.171 mg）. Ginkgo leaf tablets were purchased from Taiyuan Qianyuan Pharmacy, China. METHODS： Healthy, adult, male, Wistar rats were randomly assigned to 6 groups： sham-operation, model, XMDP （high-, middle-, and low- dose）, and Ginkgo leaf tablets. The 6 groups were subdivided into two subgroups according to administration days, i.e., 30 and 60 days, with 8 animals in each subgroup. Rats in the model, XMDP, and Ginkgo leaf tablets groups were subjected to permanent bilateral ligation of the common carotid artery to establish a vascular dementia model. At 8 days after model establishment, all groups received intragastric administration once daily of the following： 10 mL/kg normal saline in the sham-operation and model groups; 0.4, 0.2, and 0.1 g/kg XMDP in the high-, middle-, and low-dose XMDP groups, respectively; and 50 mg/kg Ginkgo leaf tablets in the Ginkgo leaf tablets group. MAIN OUTCOME MEASURES： Hematoxylin-eosin staining was used to observe appearance and to quantify the number of hippocampal CA1 pyramidal neurons. Brain-derived neurotrophic factor and nerve growth factor concentrations in brain tissues were detected by enzyme-linked immunosorbent assay. RESULTS： Following model establishment, hippocampal CA1 neurons exhibited pathological changes. Compared with the sham-operation group, the number of pyramidal neurons significantly decreased （P 〈 0.05 or P 〈 0.01）, and neurotrophic factor concentration increased in the model rats （P 〈 0.05 or P 〈 0.01）. XMDP attenuated neuronal injury in a dose-dependent manner： the number of pyramidal neurons and neurotrophic factor concentrations were significantly increased compared with the model group （P〈 0.05 or P〈 0.01）. High- and middle-dose XMDP resulted in equivalent effects to Ginkgo leaf tablets. In addition, neurotrophic factor concentrations in all XMDP groups, after 60 days of administration, were remarkably greater than corresponding concentrations at 30 days （P 〈 0.05 or P 〈 0.01 ）. CONCLUSION： Hippocampal CA1 pyramidal cells exhibited pathological injury following establishment of the vascular dementia model. Middle- and high-dose XMDP increased neurotrophic factor expression in the brain of vascular dementia rats, which suggested neuroprotection equivalent to Ginkgo leaf tablets.

Experimental study of qishen yiqi drop pill combined with bone marrow mesenchymal stem cell transplantation on angiogenesis and cardiac function in mice with myocardial infarction

Objective:To investigate the effects ofQishengyiqi drop pill combined with bone marrow mesenchymal stem cell transplantation on angiogenesis and cardiac function in mice after myocardial infarction through in vitro cell molecular biology experiments.Methods:The animals used in this experiment were male mice with eGFP+/-.Sixty mice were randomly divided into three groups(n=20):myocardial infarction group(MI+PBS),myocardial infarction+mesenchyme plasma stem cell transplantation group(MI+MSCs)and myocardial infarction+Qishenyiqi drip pill combined with mesenchymal stem cell transplantation group(MI+MSCs+QSYQ).Qishenyiqi dripping pills were prepared into a medicinal solution with a concentration of 3.9 mg/mL with distilled water.The MI+MSCs+QSYQ group was orally administered with 0.1 mL/kg/day,and the other two groups were orally administered with an equal amount of normal saline.Mice in each group were adaptively fed continuously for 2 weeks,and the myocardial infarction model was established by ligation of the anterior descending coronary artery by thoracic ligation.Twenty-four hours after the model was established,bone marrow mesenchymal stem cells were isolated from the tibia of the mice and injected intracardiacly Bone marrow-derived mesenchymal stem cells were transplanted,and multiple injections were made around the myocardial infarction area of mice.The control group was injected with the same amount of PBS.0h,3 days,7 days,and 14 days after cell transplantation,observe the stem cell morphology under a microscope;on day 7 of cell transplantation,track the expression of eGFP-positive cells with a fluorescence microscope;before modeling,14 and 21 days after cell transplantation,use Cardiac function was measured by echocardiography.After 21 days of modeling,the mice were sacrificed,and heart samples were taken.The angiogenesis of the mice was observed by immunohistochemical staining and microvascular density determination.Results:The morphological growth of transplanted stem cells was proportional to the time of cell transplantation.Compared with MI+PBS group,CD90.2 and y6A were highly expressed on the surface of bone marrow mesenchymal stem cells in MI+MSCs group and MI+MSCs+QSYQ group,while CD31 and CD117 were almost not expressed.On the 21st day after stem cell transplantation,the values of LVDd and LVSD in MI+MSCs+QSYQ group were significantly lower than those in MI+PBS group and MI+MSCs group.At the same time,LVEF and LVFS increased significantly.The results of quantitative immunohistochemical analysis showed that the angiogenesis density in the MI+MSCs+QSYQ group increased significantly,and the difference between the groups was statistically significant(P<0.05).Conclusion:Qishen Yiqi dripping pills combined with bone marrow mesenchymal stem cell transplantation can not only promote angiogenesis in mice with myocardial infarction,but also play a positive role in improving cardiac function.

Effects of adjuvant Qishen Yiqi Drop Pill therapy on renal function changes and prognosis of patients with early diabetic nephropathy

Objective: To study the effects of adjuvant Qishen Yiqi Drop Pill therapy on renal function changes and prognosis of patients with early diabetic nephropathy. Methods: The patients with early diabetic nephropathy treated in our hospital between February 2015 and April 2017 were chosen and divided into two groups by random number table, observation group received Qishen Yiqi Drop Pill combined with conventional therapy and control group accepted conventional therapy. The renal function indexes, cytokine contents and oxygen free radical generation were compared before treatment and 3 months after treatment. Results:Urine UREA levels as well as serum β2 microglobulin (β2-MG), cystatin C (CysC), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), stromal cell-derived factor-1 (SDF-1), interleukin-17 (IL-17), transforming growth factor-β1 (TGF-β1), malondialdehyde (MDA) and 8-iso-prostaglandin F2α (8-iso-PGF2α) contents of both groups were significantly lower while superoxide dismutase (SOD) and total antioxidant capacity (T-AOC) contents were significantly higher after treatment, and urine UREA level as well as serum β2-MG, CysC, TNF-α, IL-6, SDF-1, IL-17, TGF-β1, MDA and 8-iso-PGF2α contents of observation group after treatment was significantly lower than those of control group while SOD and T-AOC contents were significantly higher than those of control group. Conclusion: Adjuvant Qishen Yiqi Drop Pill therapy can improve the renal function and reduce the inflammatory response and oxidative stress response in early diabetic nephropathy.

苍耳子鼻炎滴丸对难治性变应性鼻炎的疗效和功能恢复的影响

目的 观察苍耳子鼻炎滴丸治疗难治性变应性鼻炎的疗效及其主要的药效学机制。方法 选取本院门诊经治的难治性变应性鼻炎患者102例,随机分为观察组和对照组,每组各51例。对照组予以依巴斯汀+辅舒良治疗,观察组在对照组基础上加用苍耳子鼻炎滴丸口服。疗程结束时,比较分析两组的总体疗效、临床症状和体征积分及其对血清炎症因子(IL-4、IL-6、IL-34)、免疫球蛋白E(Ig E)水平和鼻腔黏膜纤毛清除率的影响。结果 观察组总有效率(93.02%)明显高于对照组(74.36%)。疗后两组患者临床症状和体征积分、IL-4、IL-6、IL-34、Ig E水平均明显降低(P<0.05),鼻腔黏膜纤毛清除率明显提高(P<0.05),但以观察组指标改变更为显著(P<0.05)。结论 苍耳子鼻炎滴丸联合常规治疗能进一步提升难治性变应性鼻炎的临床疗效,其药效机制与抑制炎症因子及Ig E水平、促进鼻腔黏膜纤毛运动功能的恢复有关。

基于粗糙集理论和正交设计的冠心苏合滴丸制药生产工艺参数优选的方法研究

目的利用粗糙集理论和正交设计研究制药生产工艺参数之间的规律,探求优选生产工艺参数优选的数学方法。方法采用粗糙集理论方法,以冠心苏合滴丸生产工艺参数优选为案例,利用正交设计试验预处理数据,建立决策表,通过粗糙集规则模型动态分析工艺参数对结果的影响,优选最佳工艺参数。结果当冠心苏合滴丸生产工艺的参数药物与基质的配比分别与药液温度和冷却剂温度的水平逐渐增高时,溶散时限的平均水平呈现低-高-低的动态变化趋势;但当药液温度和冷却剂温度水平逐渐增高时,溶散时限的平均水平呈现动态的递减变化趋势。药物与基质的配比为1∶2,药液温度为70℃,冷却剂温度为12~14℃时,为冠心苏合滴丸生产工艺的参数的最佳组合。结论粗糙集理论能够动态、全面地分析制药生产工艺参数与试验指标之间的内在关系,提供了一种研究提高制药生产工艺质量的数学方法。

基于网络药理学和分子对接探究复方丹参滴丸治疗骨关节炎的作用机制

目的基于网络药理学和分子对接方法预测复方丹参滴丸(CDDP)治疗骨关节炎(OA)的作用机制。方法利用TCMSP数据库筛选CDDP主要化合物及靶点信息;查询GeneCards、OMIM、DisGenet数据库搜集OA相关蛋白靶点;利用Venn在线工具构建药物和疾病共同靶点;利用String 11.0平台构建蛋白质相互作用网络;采用Cytoscape 3.9.1软件构建药物-成分-靶点-疾病网络;使用R包clusterProfiler进行基因本体(GO)及京都基因与基因组百科全书(KEGG)通路富集分析;采用AutoDock Vina进行分子对接。结果CDDP与OA交集靶点有44个,KEGG通路富集发现,磷脂酰肌醇3-激酶/蛋白激酶B及白细胞介素-17信号通路等与药物作用通路相关;分子对接显示槲皮素、芹菜素和木犀草素与11个核心靶点结合良好,尤其槲皮素与金属蛋白酶9。结论CDDP可能通过多成分、多靶点、多通路共同发挥抗OA的作用.

中药复方基于Wnt/β-catenin信号通路调控糖尿病肾病研究进展

糖尿病肾病是糖尿病最常见的微血管并发症之一,也是造成终末期肾病的主要原因。Wnt/β-catenin信号通路与糖尿病肾病肾小管间质纤维化密切相关,主要通过足细胞、肾小球系膜细胞、肾小管上皮细胞等来改善糖尿病肾病。中药复方基于调控Wnt/β-catenin信号通路来改善肾脏病变及纤维化,保护肾脏功能,进而延缓病程进展,在治疗中发挥激活自噬、减少炎症反应及减弱氧化应激等作用。目前,关于中药复方基于Wnt/β-catenin信号通路的研究仍存在以下不足之处:(1)在中药复方的研究中,能够得出中药复方可通过Wnt/β-catenin信号通路发挥作用,但由于中药复方成份复杂多样,大多数仅仅发现相关性,而没有分析其具体的活性成分;(2)Wnt/β-catenin信号通路的相关研究并未深入探索该信号通路在肾纤维化中的作用机制;(3)目前关于中医药的大部分实验为动物体内实验,缺乏体外细胞的相关实验探究。今后,需加强对中药复方活性成分的研究,并开展更多的体外细胞实验,进行深层次的作用机制及靶点研究。

复方丹参滴丸联合丁苯酞治疗急性脑梗死的疗效及对患者血清炎性因子的影响

目的基于核转录因子(NF-κB)信号通路探究复方丹参滴丸联合丁苯酞对急性脑梗死(ACI)患者炎性反应的影响。方法选取2020年7月至2022年5月平顶山市第一人民医院收治的ACI患者118例,按随机数表法分为观察组和对照组各59例。对照组患者予以丁苯酞注射液治疗,观察组患者在对照组治疗的基础上联合复方丹参滴丸治疗,均连续治疗两周。治疗两周后,比较两组患者的疗效,以及治疗前、治疗一周后、两周后的美国国立研究院卒中量表(NIHSS)、简易智能状态量表(MMSE)、Barthel指数(BI)评分、脑神经因子[神经生长因子(NGF)及神经营养因子(NTF)]、NF-κB信号通路相关蛋白、mRNA和NF-κB信号通路相关因子[白细胞介素(IL)-1β、IL-6、IL-8、肿瘤坏死因子(TNF)-α]水平,同时比较两组患者治疗期间的不良反应发生情况。结果观察组患者的临床治疗总有效率为94.92%,明显高于对照组的81.36%,差异有统计学意义(P<0.05);治疗一周和两周后,两组患者的NIHSS评分均呈下降趋势,且观察组明显低于对照组,MMSE及BI评分呈升高趋势,且观察组明显高于对照组,差异均有统计学意义(P<0.05);治疗一周和两周后,两组患者的NGF、NTF均呈升高趋势,且观察组明显高于对照组,差异均有统计学意义(P<0.05);治疗一周后、两周后,两组患者的NF-κB p50蛋白、NF-κB p50 mRNA、NF-κB p65蛋白、NF-κB p65 mRNA均呈下降趋势,且观察组明显低于对照组,差异均有统计学意义(P<0.05);治疗一周后、两周后,两组患者的NF-κB信号通路相关因子IL-1β、IL-6、IL-8、TNF-α均呈下降趋势,且观察组明显低于对照组,差异均有统计学意义(P<0.05);治疗期间,观察组患者不良反应总发生率为11.86%,略高于对照组的8.47%,但差异无统计学意义(P>0.05)。结论复方丹参滴丸联合丁苯酞可通过调控NF-κB信号通路,抑制炎性反应,加速神经功能缺损恢复,临床应用效果显著且安全性较高。

复方丹参滴丸联合西医常规治疗冠心病心绞痛的回顾性队列研究

[目的]观察复方丹参滴丸联合西医常规治疗冠心病心绞痛的临床疗效,分析其临床疗效优势。[方法]采用回顾性队列研究方法,收集天津市6家医院病案管理系统中的冠心病心绞痛患者,采集时间为2014年1月—2022年6月。将这些患者分为暴露组和非暴露组,暴露组使用复方丹参滴丸联合西医常规治疗,非暴露组单独使用西医常规治疗,两组按照1∶1比例进行匹配,每组各612例。观察两组患者住院期间心血管事件发生率、临床生化指标及颈部血管彩超。[结果]暴露组谷草转氨酶、乳酸脱氢酶、C反应蛋白、凝血酶时间、D-二聚体、血糖、糖化血红蛋白、肌酐、尿酸、谷丙转氨酶、总胆红素、白细胞计数、颈动脉内中膜厚度、颈动脉斑块检出率低于非暴露组,差异具有统计学意义(P<0.05)。[结论]复方丹参滴丸联合西医常规治疗的冠心病心绞痛患者心血管事件发生率较低,凝血功能、肾功能、肝功能、血糖、血脂水平较稳定,颈动脉内中膜厚度较小,斑块发生率较低。

复方丹参滴丸联合羟苯磺酸钙治疗糖尿病性视网膜病变临床效果的meta分析

目的系统评价复方丹参滴丸辅助羟苯磺酸钙治疗糖尿病性视网膜病变(DR)的临床效果。方法检索中国知网、万方数据知识服务平台、维普网、中国生物医学文献服务系统、PubMed、Embase、Web of Science和Cochrane Library建库至2023年7月复方丹参滴丸联合羟苯磺酸钙治疗DR的临床随机对照试验。结果共纳入11项临床随机对照试验,共848例患者,观察组425例,对照组423例。meta分析结果显示,与对照组比较,试验组视野灰度值[均值差(MD)(95%CI):-0.92(-0.96,-0.88),P<0.00001]、血管瘤体积[MD(95%CI):-3.11(-3.33,-2.89),P<0.00001]、出血斑面积[MD(95%CI):-0.76(-0.85,-0.67),P<0.00001]、黄斑厚度[MD(95%CI):-55.62(-62.59,-48.65),P<0.00001]、血管内皮生长因子水平[MD(95%CI):-17.63(-21.6,-13.59),P<0.00001]、肿瘤坏死因子-α水平[MD(95%CI):-13.3(-16.09,-10.68),P<0.00001]更低,视力[MD(95%CI):0.13(0.05,0.20),P<0.00001]更好。无明显不良反应或事件发生。敏感性分析检验证实模型稳定性高,结论可信度高。结论根据目前临床证据,复方丹参滴丸与羟苯磺酸钙联用可提高DR的临床疗效。

芪参益气滴丸介导的心肌纤维化功能改变对心梗后心衰患者短期预后影响的临床研究

目的讨论芪参益气滴丸介导的心肌纤维化功能改变对心肌梗死(心梗)后心力衰竭(心衰)患者短期预后的影响。方法选择心梗后心衰患者48例,根据随机模式理论分为对照组及实验组,每组24例。对照组给予常规西医治疗,实验组在对照组的给药基础上给予芪参益气滴丸治疗。对比两组的临床疗效,甘油三酯(TG)、总胆固醇(TC)水平,左心室舒张末期内径(LVEDD)。结果实验组临床总效率为91.67%,高于对照组的66.67%,有统计学差异(P<0.05)。治疗8周后,两组TC、TG水平均低于治疗前,且实验组TC(4.23±1.71)mmol/L、TG(1.60±0.21)mmol/L均低于对照组的(5.42±2.10)、(2.22±0.87)mmol/L,有统计学差异(P<0.05)。治疗8周后,两组LVEDD均低于治疗前,且实验组LVEDD(51.21±3.36)mm低于对照组的(56.30±3.28)mm,有统计学差异(P<0.05)。结论芪参益气滴丸可以增强心梗后心衰患者的心肺能力与预后,调整血脂水平,提升临床治疗效果,可靠性高。芪参益气滴丸具有消肿定痛、抗炎、抗氧化应激、抑制纤维化、促血管形成、改变新陈代谢等功能。

复方丹参滴丸对肾功能异常患者对比剂引发的急性肾损伤的保护作用

目的:探讨复方丹参滴丸对肾功能异常患者经皮冠状动脉介入治疗(PCI)后对比剂引发的急性肾损伤(CIAKI)的作用。方法:入选天津市胸科医院心内科2019年1月—2021年12月拟行PCI的肾功能异常冠心病患者590例,采用完全随机化法将其分为对照组和复方丹参滴丸组,各295例,分别给予水化、水化联合口服复方丹参滴丸(术前1 d起,每日3次,每次10粒)治疗。观察并比较2组入院时和对比剂使用后72 h肌酐(Cr)、尿素氮(BUN)、尿白蛋白、肾小球滤过率(GFR)、白细胞介素(IL)-6、超敏C反应蛋白(hs-CRP)、β_(2)微球蛋白和肿瘤坏死因子(TNF)水平,并记录两组CIAKI发生率。结果:两组术前各项观察指标差异均无统计学意义(均P>0.05),术后复方丹参滴丸组GFR显著高于对照组(t=-6.621,P<0.01),其余观察指标均显著低于对照组(t=2.662~6.924;U=28942.500,均P<0.01),CIAKI的发生率也显著低于对照组(1.36%vs.9.83%,χ^(2)=20.061,P<0.01)。多因素Logistic回归分析表明,复方丹参滴丸对CIAKI有保护作用(OR=0.123,95%CI:0.042~0.360,P<0.01)。结论:复方丹参滴丸对肾功能异常患者PCI后CIAKI的发生有一定的保护作用。

探讨芪参益气滴丸对FFR为临界值的冠心病患者心血管临床事件的影响

目的分析芪参益气滴丸对血流储备分数(FFR)为临界值的冠心病患者心血管临床事件的影响。方法60例FFR为临界值的冠心病患者,将其以案例排序数字的奇偶性作为分组标准,排序数字为奇数的30例患者纳入对照组,排序数字为偶数的30例患者纳入试验组。对照组实施常规药物治疗,试验组在对照组的基础上联合芪参益气滴丸治疗。比较两组患者治疗前后心功能指标、西雅图心绞痛量表(SAQ)积分、中医证候积分和不良事件发生情况。结果治疗后,两组患者的左心室收缩末期内径(LVESd)、左心室舒张末期内径(LVEDd)均小于本组治疗前,且试验组患者的LVESd(32.25±3.27)mm、LVEDd(40.31±4.22)mm小于对照组的(36.81±4.69)、(46.67±5.47)mm,有统计学意义(P<0.05);两组患者的左心室射血分数(LVEF)高于本组治疗前,且试验组患者高于对照组,但差异较小,无统计学意义(P>0.05)。治疗后,两组患者的SAQ积分均较治疗前显著提高,且试验组患者SAQ积分(86.26±10.33)分高于对照组的(76.53±8.75)分,有统计学意义(P<0.05)。治疗后,两组患者的胸痛胸闷、心悸气短、头晕乏力、呼吸困难积分均较治疗前显著降低,且试验组患者胸痛胸闷、心悸气短、头晕乏力、呼吸困难积分分别为(1.02±0.25)、(0.96±0.22)、(0.95±0.24)、(0.92±0.17)分,均低于对照组的(1.34±0.29)、(1.17±0.30)、(1.19±0.31)、(1.05±0.23)分,有统计学意义(P<0.05)。试验组患者的心血管临床事件发生率3.33%低于对照组的20.00%,有统计学意义(P<0.05)。试验组患者的肝肾功能异常发生率低于对照组,但差异较小,无统计学意义(P>0.05)。结论芪参益气滴丸对FFR为临界值的冠心病患者治疗效果较好,可改善心功能指标,缓解心绞痛,有助于降低心血管临床事件的发生风险,是一种安全有效的治疗方式,值得推广应用。

冠心丹参滴丸对急性冠脉综合征合并2型糖尿病病人PCI术后生活质量及血瘀证计分的影响

目的:观察冠心丹参滴丸对急性冠脉综合征(ACS)合并2型糖尿病(T2DM)病人经皮冠状动脉介入(PCI)术后生活质量及血瘀证计分的影响。方法:在我国40所医疗中心纳入2012年2月—2015年12月行PCI治疗的ACS合并T2DM病人,以是否使用冠心丹参滴丸为暴露因素,分为冠心丹参滴丸组和常规治疗组。常规治疗组根据指南推荐进行常规西药治疗,冠心丹参滴丸组在常规西药治疗基础上加用冠心丹参滴丸每次0.4 g,每日3次,疗程为12个月。以西雅图心绞痛量表(SAQ)评分及血瘀证计分为疗效评价指标,采用广义估计方程(GEE)进行统计学分析。结果:650例病人完成了随访,其中冠心丹参滴丸组340例、常规治疗组310例。与常规治疗组比较,冠心丹参滴丸组在治疗第12个月时SAQ总分增加(P<0.05),治疗第6个月、第12个月时血瘀证计分明显下降(P<0.05或P<0.01)。结论:冠心丹参滴丸可改善ACS合并T2DM病人PCI后SAQ评分,降低血瘀证计分,提高病人生活质量。